Who Forms Stones and Why?

Slides:

Advertisements

Similar presentations

Medical Management for BPH: The Role of Combination Therapy

Advertisements

Pascal Rischmann European Urology Supplements

Volume 66, Issue 2, Pages (August 2004)

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections Rodolfo Montironi,

Management of Acute and Chronic Retention in Men

Robotic Cystectomy Versus Open Cystectomy: Are We There Yet?

Management of the Urologic Sepsis Syndrome

Shock Wave Lithotripsy for Renal and Ureteric Stones

Let the Games Begin (with EAU Approval)

Shock Wave Lithotripsy for Renal and Ureteric Stones

Martin C. Michel European Urology Supplements

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Causes of Hypocitraturia in Recurrent Calcium Stone Formers: Focusing on Urinary Potassium Excretion Somnuek Domrongkitchaiporn, MD, Wasana Stitchantrakul,

Bladder Cancer: A Major Public Health Issue

What is New in Bladder Cancer Diagnosis and Management?

Back to the Future: Introduction and Conclusions

A Novel Treatment of Premature Ejaculation

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

James N. Armitage, Stuart O. Irving, Neil A. Burgess European Urology

An Update of Current Practice in Hypospadias Surgery

Sperm Cells for Artificial Reproduction and Germ Cell Transplantation

Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in.

Richard C. Harkaway European Urology Supplements

The Economic Costs of Overactive Bladder in Germany

Volume 50, Issue 5, Pages (November 2006)

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Ian Milsom European Urology Supplements

The Importance of Testosterone Control in Prostate Cancer

Laparoscopic Cryoablation of Small Renal Masses: Technique and Results after 6-Year Experience Andrea Cestari, Giorgio Guazzoni, Nicolò Maria Buffi,

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

Long-Term Hormonal Therapy: Who Would Benefit?

Sergio Bracarda European Urology Supplements

Pharmacotherapy in Stress and Mixed Incontinence

Christian Stief European Urology Supplements

European Urology is “Your” Journal

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Ureteropelvic Junction Obstruction

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior John Dean

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Volume 4, Issue 5, Pages 2-3 (October 2006)

Profile of Silodosin European Urology Supplements

Robotic Cystectomy Versus Open Cystectomy: Are We There Yet?

Stone Disease European Urology Supplements

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Beyond Skeletal-Related Events

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Classification of Mixed Incontinence

The Impact of Premature Ejaculation on Partners and Relationships

Emmanuel Chartier-Kastler, Andrea Tubaro European Urology Supplements

Diagnosis and Management of Cryptorchidism

Epidemiology and Demographics of Prostatitis

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Volume 163, Issue 2, (October 2015)

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B. Tombal European Urology.

Presentation transcript:

Who Forms Stones and Why? Hans-Göran Tiselius European Urology Supplements Volume 10, Issue 5, Pages 408-414 (October 2011) DOI: 10.1016/j.eursup.2011.07.002 Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 1 Simplified overview of steps in calcium oxalate stone formation. AP=ion-activity product; CaOx=calcium oxalate; CaP=calcium phosphate. European Urology Supplements 2011 10, 408-414DOI: (10.1016/j.eursup.2011.07.002) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 2 Relationship between pH and the ion-activity product of uric acid. AP=ion-activity product. European Urology Supplements 2011 10, 408-414DOI: (10.1016/j.eursup.2011.07.002) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 3 Relationship between pH and the ion-activity product of cystine. AP=ion-activity product. European Urology Supplements 2011 10, 408-414DOI: (10.1016/j.eursup.2011.07.002) Copyright © 2011 European Association of Urology Terms and Conditions